Novel biomarkers in acute heart failure

被引：37

作者：

Yanavitski M. ^{[1
]}

Givertz M.M. ^{[1
]}

机构：

[1] Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115

来源：

Current Heart Failure Reports | 2011年 / 8卷 / 3期

关键词：

Adiponectin; Biomarkers; CgA; Chromogranin A; Cystatin C; Endoglin; Galectin-3; Heart failure; Leptin; Midregional pro-adrenomedullin; MRproADM; Neutrophil gelatinase-associated lipocalin; NGAL; Resistin; ST2;

D O I：

10.1007/s11897-011-0065-5

中图分类号：

学科分类号：

摘要：

Heart failure goes beyond mechanical dysfunction and involves an interplay of multiple pathophysiologic mechanisms, including inflammation, tissue remodeling, neurohormonal and endocrine signaling, and interactions with the renal and nervous systems. This article highlights some novel biomarkers that may aid in diagnosis, treatment, and prognosis of acute heart failure, specifically focusing on ST2, endoglin, galectin-3, cystatin C, neutrophil gelatinase-associated lipocalin, midregional pro-adrenomedullin, chromogranin A, adiponectin, resistin, and leptin and their emerging clinical roles. © Springer Science+Business Media, LLC 2011.

引用

页码：206 / 211

页数：5

共 45 条

[1]

Roger V.L., Go A.S., Lloyd-Jones D.M., Et al., Heart disease and stroke statistics-2011 update: A report from the American Heart Association, Circulation, 123, (2011)

[2]

Koelling T.M., Chen R.S., Lubwama R.N., L'Italien G.J., Eagle K.A., The expanding national burden of heart failure in the United States: The influence of heart failure in women, American Heart Journal, 147, 1, pp. 74-78, (2004)

[3]

Haldeman G.A., Croft J.B., Giles W.H., Rashidee A., Hospitalization of patients with heart failure: National hospital discharge survey, 1985 to 1995, American Heart Journal, 137, 2, pp. 352-360, (1999)

[4]

Palazzuoli A., Gallotta M., Quatrini I., Et al., Natriuretic peptides (BNP and NT-proBNP): Measurement and relevance in heart failure, Vasc Health Risk Manag., 6, pp. 411-418, (2010)

[5]

Braunwald E., Biomarkers in heart failure, N Engl J Med., 358, pp. 2148-2159, (2008)

[6]

Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S.-I., Solomon S.D., Rouleau J.-L., Lee R.T., Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction, Circulation, 106, 23, pp. 2961-2966, (2002)

[7]

Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S.-I., Rouleau J.-L., Lee R.T., Identification of serum soluble ST2 receptor as a novel heart failure biomarker, Circulation, 107, 5, pp. 721-726, (2003)

[8]

Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N.J., Lee R.T., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system, Journal of Clinical Investigation, 117, 6, pp. 1538-1549, (2007)

[9]

Januzzi Jr. J.L., Peacock W.F., Maisel A.S., Chae C.U., Jesse R.L., Baggish A.L., O'Donoghue M., Sakhuja R., Chen A.A., Van Kimmenade R.R.J., Lewandrowski K.B., Lloyd-Jones D.M., Wu A.H.B., Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study, Journal of the American College of Cardiology, 50, 7, pp. 607-613, (2007)

[10]

Manzano-Fernandez S., Mueller T., Pascual-Figal D., Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction, Am J Cardiol., 107, pp. 259-267, (2011)

← 1 2 3 4 5 →